Antibiotic pill study to prevent repeat belly infection in liver disease
Part of Digestive system, Infections clinical trials.
This study tests whether taking norfloxacin plus itopride helps prevent another episode of spontaneous bacterial peritonitis (a serious belly infection) in people with cirrhosis and fluid buildup in the abdomen. It compares that combo to norfloxacin alone to see which approach better lowers repeat infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cirrhosis (scarring of the liver) with fluid buildup in your belly (ascites).
- You have had a past episode of spontaneous bacterial peritonitis (SBP).
- You must not be allergic to, or have a medical reason to avoid, norfloxacin or itopride.
- You cannot have taken antibiotics in the last 2 weeks.
- You must not have liver cancer (hepatocellular carcinoma) or another type of active tumor (neoplasm).
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two antibiotic treatments for spontaneous bacterial peritonitis—one taken by mouth (gemifloxacin) versus one given through a vein (cefotaxime). It may help find the best way to treat this infection and improve recovery.
This study looks at patients with cirrhosis who have had a first infection in the belly fluid (called SBP). The goal is to find out how often this infection returns and what factors might predict it coming back.
This trial tests whether removing infected fluid from the belly early helps people with cirrhosis and an infection called SBP. It may reduce the chance of complications and improve recovery.
This study looks at whether simple blood tests (platelet count, sodium level, and a new index called ALBI) can help predict a serious infection in the belly fluid (spontaneous bacterial peritonitis) in people with cirrhosis and ascites.
This study tests a new scoring system to predict if patients with liver cirrhosis and ascites (fluid in the belly) will develop a serious infection called spontaneous bacterial peritonitis. It aims to help doctors identify high-risk patients earlier so they can be monitored more closely.
This study tests whether adding a probiotic to standard antibiotics helps treat an infection in the abdominal fluid of people with cirrhosis (called spontaneous bacterial peritonitis) and prevents it from coming back.
Hear when a new Spontaneous Bacterial Peritonitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.